Symvess, or the ATEV™ (acellular tissue engineered vessel), is a first-in-class bioengineered human tissue that is designed to be a universally implantable vascular conduit for use in arterial ...

The U.S. Food and Drug Administration (FDA) granted a full approval for Symvess on December 19, 2024 for use in adults as a vascular conduit for extremity arterial injury when urgent ...

Novo Nordisk, Helixmith, and others .Key Peripheral Artery Disease Therapies: Collategene (beperminogene perplasmid), REX-001, ACP-01, Honedra, Human Acellular Vessel (HAV), Semaglutide ...

Caladrius Biosciences, Humacyte, Inc., Novo Nordisk, Helixmith, and others • Key Peripheral Artery Disease Therapies: Collategene (beperminogene perplasmid), REX-001, ACP-01, Honedra, Human Acellular ...

Pluristyx has developed a clinical-grade manufacturing process for using a licensed Mad7 gene editing technology to block Human Leukocyte Antigen (HLA) markers expression. Humacyte is optimizing a ...

acellular tissue engineered vessel (sdATEV) in coronary artery bypass grafting (CABG). The Company’s current plans for filing an IND are based on the outcome of a recent meeting held with the ...

Humacyte’s Biologics License Application for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in ...

DURHAM, N.C. - Humacyte, Inc. (NASDAQ:HUMA), a biotechnology firm specializing in bioengineered human tissues with a current market capitalization of $580 million, and Pluristyx, Inc., a provider of ...

Plans for filing an IND was agreed with the FDA in a recent meeting - - Positive preclinical results of the small-diameter ATEV were recently presented at The American Heart Association's Scientific ...